SWP
NRSN icon

Stratos Wealth Partners’s NeuroSense Therapeutics NRSN Stock Holding History

Stratos Wealth Partners’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,000
Closed -$24K – 1471
2024
Q4 		$24K Buy
+20,000
New +$23K ﹤0.01% 1440

Other funds holding NRSN

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HC
Hurley Capital New York $187M AUM 23.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Stratos Wealth Partners's NRSN Position: Q1 2025 in Review

Stratos Wealth Partners sold out of NeuroSense Therapeutics (NRSN) in Q1 2025, closing a stake of 20,000 shares — an estimated $24K sold.

Stratos Wealth Partners first reported a position in NRSN in Q4 2024 and held it in 1 quarter. The position peaked at $24K in Q4 2024. 11 funds tracked by Wall St. Rank hold NRSN as of Q1 2025.

  • Stratos Wealth Partners reported no remaining NeuroSense Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Stratos Wealth Partners sold 20,000 NeuroSense Therapeutics shares in Q1 2025, an estimated $24K.
  • Stratos Wealth Partners first reported a position in NeuroSense Therapeutics in Q4 2024 and held it in 1 quarter.
  • Stratos Wealth Partners's NeuroSense Therapeutics position peaked at $24K in Q4 2024.
  • 11 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q1 2025.

Based on Stratos Wealth Partners's 13F filing for Q1 2025, filed 30 Apr 2025.